WPL: Dirk Jochmans
Generation of human monoclonal antibodies as potential therapeutic antibodies.
Fully human monoclonal antibodies will be generated and tested with replication competent virus to select mono-specific or cross-neutralising monoclonal antibodies. Next the epitopes will be identified. The most interesting monoclonal antibodies will be characterized in molecular detail within WP1. Main location: currently unknown
Identification small molecule compounds with the capacity to inhibit virus entry.
Initially our research will target the most clinically relevant and wide-spread virus types (CBV3 and EV71). A compound library of ~10.000 synthetic and semi-synthetic compounds (derived from natural products) will be screened with live virus to allow for discovery of inhibitors of all processes within the virus replication cycle. The aim is to obtain compounds with broad-spectrum anti-picorna activity. The selected compounds and their working-mechanism will be characterized which in turn will provide novel insights into the replication strategy of picornaviruses. Main location: REGA